当前位置: 首页 >> 检索结果
共有 62501 条符合本次的查询结果, 用时 6.343863 秒

221. Highlights From the Circulation Family of Journals.

来源: Circulation. 2025年152卷14期1028-1033页

222. Response by Zweck and Møller to Letter Regarding Article, "Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial".

作者: Elric Zweck.;Jacob Eifer Møller.
来源: Circulation. 2025年152卷14期e274-e275页

223. Cannabis Use Linked to Substantial Heart Risks.

作者: Bridget M Kuehn.
来源: Circulation. 2025年152卷14期1026-1027页

224. Fibroblasts Are the Primary Contributors to a Disrupted Micro-Environment in End-Stage Pediatric Hypertrophic Cardiomyopathy.

作者: Hanna J Tadros.;Diwakar Turaga.;Yi Zhao.;Chang-Ru Tsai.;Iki A Adachi.;Xiao Li.;James F Martin.
来源: Circ Genom Precis Med. 2025年e005192页
Hypertrophic cardiomyopathy (HCM) is a relatively rare but debilitating diagnosis in the pediatric population, and patients with end-stage HCM require heart transplantation. Here, we have examined the transcriptome in ventricular tissue from this patient group to identify cell states and underlying cellular processes unique to pediatric HCM.

225. Contemporary Burden of Cardiovascular Disease in Pregnancy: Insights From a Real-World Pregnancy Electronic Health Record Cohort.

作者: Emily S Lau.;Valentina D'Souza.;Yunong Zhao.;Christopher Reeder.;Rachel Goldberg.;Micayla Flores.;Katherine E Economy.;Mahnaz Maddah.;Shaan Khurshid.;Patrick T Ellinor.;Jennifer E Ho.
来源: Circulation. 2025年152卷15期1044-1055页
Cardiac and vascular complications are the leading causes of maternal mortality and morbidity, but the contemporary burden of and secular trends in pregnancy-related cardiovascular complications are not well-characterized. We developed a multi-institutional electronic health record-based pregnancy cohort with rigorously defined cardiovascular outcomes to examine trends in prevalence of maternal cardiovascular comorbidities and cardiovascular disease (CVD) and incidence of pregnancy-related cardiovascular complications.

226. CARS2 Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health Substudy.

作者: Jessica A Regan.;Jordan Franklin.;Kalyani Kottilil.;Nicholas Cauwenberghs.;Kenneth W Mahaffey.;Pamela S Douglas.;Fatima Rodriguez.;Francois Haddad.;Adrian F Hernandez.;Svati H Shah.;Lydia Coulter Kwee.; .
来源: Circ Genom Precis Med. 2025年18卷5期e005073页

227. Digging Deeper Into Cardiovascular Plasma Proteomics: Opportunities and Limitations of Current Platforms.

作者: Pich Chhay.;Owen Tang.;Lizhuo Ai.;Stuart J Cordwell.;Michael P Gray.;Jean Y H Yang.;Jennifer E Van Eyk.;Peter J Psaltis.;Gemma A Figtree.
来源: Circ Genom Precis Med. 2025年18卷5期e005198页
Coronary artery disease remains the leading cause of death worldwide. One of the greatest developments in preventive cardiology has been the identification and treatment of standard modifiable risk factors associated with coronary artery disease. However, despite advances in the management of standard modifiable risk factors, there is an escalating number of patients who continue to present with acute coronary syndromes, a trend that is particularly concerning given the decreasing age-adjusted incidence rates of these conditions. This persistent clinical challenge underscores the urgency to explore alternative approaches for early detection and improved risk stratification. In recent years, the emergence of proteomics technologies has brought forth promising avenues for the discovery of novel biomarkers that hold the potential to revolutionize the timely detection and management of coronary artery disease. Proteomics enables the high throughput and often unbiased analysis of protein abundance, modifications, and interactions within pathways relevant to cardiovascular disease pathogenesis. Of particular importance is the capability to detect low-abundance proteins including those with currently unknown functions. While the functional assessment of these proteins aligns more with mechanistic studies, their role in biomarker discovery is equally important. Such detection may provide new insights into cardiac pathophysiology, including potential new markers for early disease detection and risk assessment. Although the latest proteomics technology and bioinformatic approaches do provide the opportunity for novel discoveries, understanding the limitations of each technology platform is important. This review provides an updated overview of major proteomic platforms and discusses their methodological strengths, constraints, and applications, using recent coronary artery disease studies as illustrative examples. By integrating proteomics data with clinical information, including advanced noninvasive imaging techniques and other omics disciplines, such as genomics and metabolomics, we can deepen our understanding of disease mechanisms and improve risk stratification. Although the discovery of novel biomarkers represents a significant step forward in the field, their true clinical value is contingent upon their rigorous validation in clinical trials and implementation studies. With our current capabilities and emerging advancements, we are well-positioned to advance proteomics-guided precision medicine in cardiovascular care over the coming decade.

228. Complete Revascularization in Older Patients With Myocardial Infarction With or Without Complex Nonculprit Lesions.

作者: Alberto Sarti.;Andrea Erriquez.;Beatrice Dal Passo.;Gianni Casella.;Vincenzo Guiducci.;Raul Moreno.;Javier Escaned.;Federico Marchini.;Marta Cocco.;Filippo Maria Verardi.;Stefano Clò.;Serena Caglioni.;Jacopo Farina.;Emanuele Barbato.;Giuseppe Vadalà.;Caterina Cavazza.;Alessandro Capecchi.;Francesco Gallo.;Gianluca Campo.;Simone Biscaglia.
来源: Circ Cardiovasc Interv. 2025年18卷11期e015902页
The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) showed the superiority of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease. Whether this result applies equally to patients at higher risk of ischemic events due to nonculprit lesion complexity is unclear.

229. Characterizing the Immune Response in Pig-to-human Heart Xenografts Using a Multimodal Diagnostic System.

作者: Alessia Giarraputo.;Erwan Morgand.;Jeffrey Stern.;Fariza Mezine.;Guillaume Coutance.;Valentin Goutaudier.;Aurelie Sannier.;Anais Certain.;Thierry Hauet.;Sebastien Giraud.;Thomas Kerforne.;Geraldine Allain.;David Ayares.;Karen Khalil.;Jaqueline Kim.;Sapna Mehta.;Navneet Narula.;Alex Reyentovich.;Deane Smith.;Renaud Tissier.;Tajinderpal Saraon.;Bernard Kadosh.;Michael DiVita.;Randal Goldberg.;Harvey Pass.;Massimo Mangiola.;Patrick Bruneval.;Adam Griesemer.;Nader Moazami.;Robert A Montgomery.;Alexandre Loupy.
来源: Circulation. 2025年
Porcine genome editing has revolutionized xenotransplantation, recently enabling the first pig-to-human heart xenotransplants. However, the xeno-immune response in heart xenografts remains largely unexplored. This study aimed to precisely characterize the xeno-immune response and injury in two heart xenografts, transplanted from 10-gene-edited pigs into brain-dead human recipients.

230. Reverse Remodeling Following Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy: As Transformed as Otto's Heart?

作者: Lan Shen.;Timothy C Wong.
来源: Circ Cardiovasc Imaging. 2025年18卷10期e018959页

231. Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock.

作者: Christian Jung.;Alexander Lang.;Dragos Andrei Duse.;Raphael Romano Bruno.;Janine Pöss.;Georg Wolff.;Uta Ceglarek.;Uwe Zeymer.;Georg Fuernau.;Elric Zweck.;Steffen Desch.;Anne Freund.;Berend Isermann.;Susanne Pfeiler.;Bernhard Wernly.;Malte Kelm.;Holger Thiele.;Norbert Gerdes.
来源: Circ Heart Fail. 2025年e012890页
Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI) leading to poor outcomes. Specific biomarkers, with subsequent validation of their prognostic relevance in CS, are urgently needed to improve therapies and outcomes. Accordingly, the present study investigated the plasma proteome using proximity extension assay technology to identify novel specific biomarkers with subsequent validation of their prognostic relevance in CS.

232. Modified Unipolar Return Pulsed Field Ablation in Ventricular Myocardium.

作者: Maria Terricabras.;Peter Lombergar.;Terenz Escartin.;Bor Kos.;Philippa Krahn.;Jennifer Barry.;Graham Wright.;Tomaž Jarm.;Jernej Štublar.;Matej Kranjc.;Nicolas Coulombe.;Lars Mattison.;Daniel C Sigg.;Damijan Miklavčič.;Atul Verma.
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e014006页
Various pulsed field ablation (PFA) parameters have been proposed to improve lesion depth. This study evaluated a modified unipolar return PFA system to create deep lesions in healthy and infarcted ventricular myocardia.

233. Prevalence and Clinical Impact of Postural Orthostatic Tachycardia Syndrome in Highly Symptomatic Long COVID.

作者: Mikael Björnson.;Klara Wijnbladh.;Anna Törnberg.;Anna Svensson-Raskh.;Annie Svensson.;Marcus Ståhlberg.;Michael Runold.;Artur Fedorowski.;Malin Nygren-Bonnier.;Judith Bruchfeld.
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e013629页
The incidence of postural orthostatic tachycardia syndrome (POTS) in long COVID has been a growing concern since the first cases were reported in 2021. The aim of this study was to assess the prevalence and clinical impact of POTS in a series of well-characterized patients with long COVID.

234. Prediction of Atrial Fibrillation From the ECG in the Community Using Deep Learning: A Multinational Study.

作者: Luisa C C Brant.;Antônio H Ribeiro.;Oseiwe B Eromosele.;Marcelo M Pinto-Filho.;Sandhi M Barreto.;Bruce B Duncan.;Martin G Larson.;Emelia J Benjamin.;Antonio L P Ribeiro.;Honghuang Lin.
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e013734页
We aimed to refine and validate a deep neural network model from the ECG to predict atrial fibrillation (AF) risk, using samples from diverse backgrounds: the Framingham Heart Study (FHS), UK Biobank, and Estudo Longitudinal da Saúde do Adulto (ELSA-Brasil). We compared the model's performance to the clinical Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (CHARGE-AF) risk score and evaluated the association with other cardiovascular outcomes.

235. Inhibition of Satellite Glial Cell Activation in Stellate Ganglia Prevents Ventricular Arrhythmogenesis and Remodeling After Myocardial Infarction.

作者: Zhen Zhou.;Hanyu Zhang.;Hongbo Xiong.;Ke-Qiong Deng.;Meng Zheng.;Yongkang Zhang.;Zhendong Xu.;Ruifeng Tian.;Tong Zhang.;Xiangjie Kong.;Yingying Hu.;Yinhua Luo.;Huanhuan Cai.;Di Fan.;Qing K Wang.;Bo He.;Qiongxin Wang.;Zhibing Lu.
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e013866页
Hyperactivity of sympathetic neurons in the stellate ganglia (SG) contributes to ventricular arrhythmias and remodeling postmyocardial infarction (MI). However, the role of satellite glial cells (SGCs) surrounding the neurons in this process remains unknown.

236. Significance of Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Negative Endomyocardial Biopsies: A Dawn of a New Era.

作者: Cathrine M Moeller.;Andrea Fernandez Valledor.;Daniel Oren.;Salwa Rahman.;Julia Baranowska.;Adi Hertz.;Ersilia M DeFilippis.;Changhee Lee.;Matthew C Regan.;Amit Oren.;Afsana Rahman.;Carolyn Hennecken.;Ruben Salazar.;Elena M Donald.;Dor Lotan.;David T Majure.;Melana Yuzefpolskaya.;Paolo C Colombo.;Jayant K Raikhelkar.;Justin A Fried.;Kevin J Clerkin.;Farhana Latif.;Gabriel T Sayer.;Nir Uriel.
来源: Circ Heart Fail. 2025年18卷11期e012787页
The purpose of the current study was to investigate the clinical implications of elevated donor-derived cell-free DNA (dd-cfDNA) levels in heart transplantation recipients without evidence of rejection observed on endomyocardial biopsy.

237. Rapid Electrocardiographic Protocol for Identifying Ventricular Arrhythmias From Specific Sites of the Right Coronary Cusp.

作者: Cheng Zheng.;Wu-Min Hu.;Wei-Qian Lin.;Yi-Fan Lin.;Jia-Meng Shao.;Bing Shen.;Rong-Hua Liu.;Xiao Lu.;Guo-Juan Xu.;Lucia D'Angelo.;Shea Michaela James.;Jia-Feng Lin.
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e012936页

238. Increasing Extracellular Volume Fraction on Coronary CTA in Patients With Coronary Microvascular Dysfunction.

作者: Kodai Sayama.;Yoshihisa Kanaji.;Eisuke Usui.;Masahiro Hada.;Tatsuhiro Nagamine.;Hiroki Ueno.;Kai Nogami.;Mirei Setoguchi.;Tomohiro Tahara.;Hikaru Shimosato.;Takahiro Watanabe.;Tatsuya Sakamoto.;Rika Sai.;Takashi Mineo.;Nobutaka Wakasa.;Masahiro Hoshino.;Tomoyo Sugiyama.;Taishi Yonetsu.;Tetsuo Sasano.;Tsunekazu Kakuta.
来源: Circ Cardiovasc Imaging. 2025年18卷11期e018368页
Coronary computed tomography angiography (CCTA) could evaluate myocardial fibrosis as well by estimating extracellular volume fraction (ECV). While coronary microvascular dysfunction (CMD) has been increasingly recognized as an important pathophysiological mechanism underlying chest pain, the association between CMD in angina with nonobstructive coronary artery disease (ANOCA) and CCTA-derived ECV remains to be elucidated. We sought to evaluate the association between CCTA-derived ECV and CMD in patients with ANOCA.

239. Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation.

作者: Kenneth A Ellenbogen.;Ali Khoynezhad.;Mark La Meir.;Carlo de Asmundis.;Jayanthi N Koneru.;John Johnkoski.;Kevin Rist.;Mubashir Mumtaz.;Michael G Link.;Joris R de Groot.;Antoine H G Driessen.;Mark Y Lee.;Steven J Hoff.;David Bello.;Gansevoort Dunnington.;Susan Eisenberg.;Margot Vloka.;Benedict J Taylor.;Stephen D Jones.;Jonathan M Philpott.;Thomas M Beaver.;William M Miles.;Junaid H Khan.;Steven Kang.;Gaurang D Gandhi.;Eric J Okum.;Nitish Badhwar.;Tina Baykaner.;Anson M Lee.;Paul A Vesco.;J Michael Smith.;Sydney Gaynor.;Ken Frazier.;Randall J Lee.;Vigneshwar Kasirajan.
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e013692页
Despite advances in endocardial catheter ablation (ECA) for persistent atrial fibrillation (PersAF), undertreatment persists, especially in ECA nonresponders and in longstanding PersAF (LSPersAF), with disappointing ablation results. These patients need effective clinical treatment options.

240. Long-Term Arrhythmic Outcomes of KCNJ2 Variant Carriers in Japan.

作者: Koichi Kato.;Yosuke Higo.;Takanori Aizawa.;Megumi Fukuyama.;Keiko Sonoda.;Takashi Hisamatsu.;Yusuke Fujii.;Hideki Itoh.;Takeru Makiyama.;Seiko Ohno.;Yoshihisa Nakagawa.;Minoru Horie.
来源: Circ Genom Precis Med. 2025年18卷5期e005188页
共有 62501 条符合本次的查询结果, 用时 6.343863 秒